Iantrek Announces Positive Efficacy and Safety Profile of its Bio-Interventional Technology

Iantrek Corporation today announced positive results from its 2-year prospective clinical study evaluating its bio-reinforced cyclodialysis technology. The study, published in Ophthalmology Science, affirms the safety and efficacy of Iantrek’s bio-interventional technology to enhance uveoscleral outflow in patients with open-angle glaucoma undergoing cataract surgery. 

The study found 74% of treated eyes achieved a ≥20% reduction in intraocular pressure (IOP) at 2 years with the same or fewer glaucoma medications. Mean IOP was reduced by 34%, and use of IOP-lowering medications decreased by >60%. Notably, there were no serious ocular adverse events reported. 

“This study highlights a meaningful advancement in glaucoma surgery by safely and effectively targeting the uveoscleral pathway through a minimally invasive, bio-interventional approach,” Robert N. Weinreb, MD, Distinguished Professor and Chair of Ophthalmology at the University of California, San Diego, said in a recent press release. “This represents a groundbreaking, hardware-free solution using next-generation, homologous bio-tissue materials for superior biocompatibility.”

The study results were further validated by a separate recent presentation at the 2025 American Glaucoma Society Annual Meeting by Leon W. Herndon, MD, Professor of Ophthalmology at Duke University. Dr. Herndon shared the 2-year outcomes of the CREST study, the largest surgical glaucoma cohort to date, which demonstrated sustained IOP reduction with a favorable safety profile. 

Iantrek is the only company with FDA-approved technology to surgically enhance uveoscleral outflow pathways to lower intraocular pressure. It is designed to be performed either in stand-alone or in combination with another ophthalmic surgical procedure. The company announced they have plans for broad commercialization later this year.